{"organizations": [], "uuid": "2b98fdad1417dbb1eaa23233513f2ca369146477", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-jan-25-idUSL8N1PJ5H0", "country": "US", "domain_rank": 408, "title": "Swiss stocks - Factors to watch on Jan 25", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T13:54:00.000+02:00", "replies_count": 0, "uuid": "2b98fdad1417dbb1eaa23233513f2ca369146477"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-jan-25-idUSL8N1PJ5H0", "ord_in_thread": 0, "title": "Swiss stocks - Factors to watch on Jan 25", "locations": [], "entities": {"persons": [{"name": "julius baer", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "saudi arabia", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "clariant", "sentiment": "none"}, {"name": "clariant", "sentiment": "none"}, {"name": "schlatter group", "sentiment": "none"}, {"name": "spark therapeutics inc", "sentiment": "none"}, {"name": "ebitda", "sentiment": "none"}, {"name": "sabic", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, Jan 25 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,537 points on Thursday, according to premarket indications by bank Julius Baer .\nHere are some of the main factors that may affect Swiss stocks on Thursday:\nCLARIANT Activist investor White Tale has sold its nearly 25 percent stake in speciality chemicals group Clariant to Saudi Arabiaâ€™s SABIC, the Swiss group said on Thursday.\nFor more news, click on\nCOMPANY STATEMENTS * Aryzta reduced its guidance for its 2018 financial year, saying it expected EBITDA to be 20 percent below 2017 levels, after its business weakened in Europe and the United States.\n* Novartis: Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Novartis.\n* Schlatter Group said it had increased its net sales in the 2017 financial year by 11.7 percent to 101.1 million Swiss francs ($107.23 million) and realised a lower order intake of 94.6 million Swiss francs to the previous year.\n* Real estate investment fund La Fonciere will undergo a 10-for-one split as of Feb 21 to boost trading liquidity.\n* HBM Healthcare Investments said it closed the third quarter of the 2017/2018 financial year, as at 31 December 2017, with a profit of 72.0 million Swiss francs. This takes profit for the first nine months of the financial year to 85.6 million francs.\n* Huber+Suhner said it increased its annual sales by 5 percent in 2017 to 744 million Swiss francs, while order intake rose 10.7 percent to 826 million francs.\n* Valora said Bernhard Heusler has decided not to stand for re-election and will leave the board of directors in April 2018.\n* Belimo Group said its net sales rose by 8.7 percent to 579.9 million Swiss francs in 2017.\n* Evolva said its product revenues increased to 2.0 million Swiss francs in 2017 from 1.1 million francs in 2016, in-line with previous guidance.\n* Baloise said it has expanded its digital services line-up by launching Mobly, a driver assistance and used car advisory system, in Belgium.\n* Aventron said it was building its first wind park In Norway.\nECONOMY $1 = 0.9428 Swiss francs Reporting by Zurich newsroom\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T13:54:00.000+02:00", "crawled": "2018-01-25T10:10:10.001+02:00", "highlightTitle": ""}